Nisa Investment Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$49.5K Sell
1,218
-459
-27% -$15.8K ﹤0.01% 1858
2026
Q1
$52.8K Buy
1,677
+515
+44% +$14.9K ﹤0.01% 1647
2025
Q4
$28.8K Buy
1,162
+288
+33% +$5.78K ﹤0.01% 1805
2025
Q3
$14.2K Sell
874
-70
-7% -$993 ﹤0.01% 2140
2025
Q2
$12.4K Sell
944
-112
-11% -$1.61K ﹤0.01% 2169
2025
Q1
$23.2K Buy
1,056
+7
+0.7% +$184 ﹤0.01% 1820
2024
Q4
$28K Buy
1,049
+67
+7% +$2.13K ﹤0.01% 1834
2024
Q3
$26.2K Buy
982
+96
+11% +$1.91K ﹤0.01% 1820
2024
Q2
$16K Buy
886
+632
+249% +$11K ﹤0.01% 2018
2024
Q1
$4.63K Buy
254
+37
+17% +$588 ﹤0.01% 2129
2023
Q4
$2.37K Sell
217
-1,310
-86% -$9.2K ﹤0.01% 2173
2023
Q3
$8.75K Buy
1,527
+1,502
+6,008% +$10.2K ﹤0.01% 2200
2023
Q2
$194 Buy
+25
New +$211 ﹤0.01% 2711
2023
Q1
Sell
-2,900
Closed -$26K 2577
2022
Q4
$26K Sell
2,900
-15,300
-84% -$143K ﹤0.01% 1976
2022
Q3
$178K Buy
18,200
+15,300
+528% +$155K ﹤0.01% 1301
2022
Q2
$23K Buy
+2,900
New +$21.9K ﹤0.01% 2010
2021
Q4
Sell
-10,257
Closed -$170 2270
2021
Q3
$170 Buy
+10,257
New +$185K ﹤0.01% 1468

Other funds holding EWTX

Nisa Investment Advisors's EWTX Position: Q2 2026 in Review

Nisa Investment Advisors reduced its Edgewise Therapeutics (EWTX) stake by 27% in Q2 2026, selling an estimated $15.8K and leaving 1,218 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Nisa Investment Advisors first reported a position in EWTX in Q3 2021 and has held it in 17 quarters since. The position peaked at $178K in Q3 2022. 68 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Nisa Investment Advisors held 1,218 shares of Edgewise Therapeutics worth $49.5K as of Q2 2026.
  • Nisa Investment Advisors sold 459 Edgewise Therapeutics shares in Q2 2026, an estimated $15.8K.
  • Edgewise Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1858 holding.
  • Nisa Investment Advisors first reported a position in Edgewise Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Nisa Investment Advisors's Edgewise Therapeutics position peaked at $178K in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.